Cargando…

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition

Detalles Bibliográficos
Autores principales:	Zhang, Kai-li, Shen, Qian-qian, Fang, Yan-feng, Sun, Yi-ming, Ding, Jian, Chen, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468349/ https://www.ncbi.nlm.nih.gov/pubmed/32060412 http://dx.doi.org/10.1038/s41401-019-0344-3

Ejemplares similares

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

AZD9291-induced Acute Interstitial Lung Disease
por: Nie, Ke-Ke, et al.
Publicado: (2016)

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
por: Chen, Tianxiang, et al.
Publicado: (2019)

AZD9291-resistant non-small cell lung cancer cell-derived exosomal lnc-MZT2A-5:1 induces the activation of fibroblasts
por: Song, Liwei, et al.
Publicado: (2021)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

Author Correction: Ybx1 fine-tunes PRC2 activities to control embryonic brain development
por: Evans, Myron K., et al.
Publicado: (2023)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2022)

Correction: Dispersal of PRC1 condensates disrupts polycomb chromatin domains and loops
por: Williamson, Iain, et al.
Publicado: (2023)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
por: Li, Wen, et al.
Publicado: (2021)

Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia
por: Ntziachristos, Panagiotis, et al.
Publicado: (2012)

Author Correction: G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin
por: Wang, Ya-fang, et al.
Publicado: (2020)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2023)

Conversion of random X-inactivation to imprinted X-inactivation by maternal PRC2
por: Harris, Clair, et al.
Publicado: (2019)

Structure and Function of the Polycomb Repressive Complexes PRC1 and PRC2
por: Angrand, Pierre-Olivier
Publicado: (2022)

Correction to ‘PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation’
Publicado: (2023)

Author Correction: Bio-inspired nitric-oxide-driven nanomotor
por: Wan, Mimi, et al.
Publicado: (2019)

Author Correction: Skin tolerant inactivation of multiresistant pathogens using far-UVC LEDs
por: Glaab, Johannes, et al.
Publicado: (2022)

Author Correction: The transcriptional repressor complex FRS7-FRS12 regulates flowering time and growth in Arabidopsis
por: Ritter, Andrés, et al.
Publicado: (2018)

Variant PCGF1-PRC1 links PRC2 recruitment with differentiation-associated transcriptional inactivation at target genes
por: Sugishita, Hiroki, et al.
Publicado: (2021)

Author Correction: Bayesian reassessment of the epigenetic architecture of complex traits
por: Banos, Daniel Trejo, et al.
Publicado: (2020)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

Authors' Correction
Publicado: (1963)

Author Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4 (+) High-Grade Osteosarcoma
por: Zhang, Wu, et al.
Publicado: (2021)

Author Correction: Glycosylation Significantly Inhibits the Aggregation of Human Prion Protein and Decreases Its Cytotoxicity
por: Yi, Chuan-Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kv37kvva0e1kt9uqgi9dbktsuc